Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1322

1.

Perspectives on the Changing Landscape of Measuring Cardiovascular Risk Related to LDL.

El-Khoury JM, Remaley AT, Nordestgaard BG, Kaufman HW, Mora S, Cao J, Meeusen JW.

Clin Chem. 2019 Nov 7. pii: clinchem.2019.307306. doi: 10.1373/clinchem.2019.307306. [Epub ahead of print] No abstract available.

PMID:
31699699
2.

Laboratory Blood-Based Testing for Non-Lyme Disease Tick-Borne Infections at a National Reference Laboratory.

Lee-Lewandrowski E, Chen Z, Branda J, Baron J, Kaufman HW.

Am J Clin Pathol. 2019 Oct 4. pii: aqz139. doi: 10.1093/ajcp/aqz139. [Epub ahead of print]

PMID:
31584611
3.

Trends in Hepatitis B Infection and Immunity among Women of Childbearing Age in the United States.

Kushner T, Chen Z, Tressler S, Kaufman H, Feinberg J, Terrault NA.

Clin Infect Dis. 2019 Aug 26. pii: ciz841. doi: 10.1093/cid/ciz841. [Epub ahead of print]

PMID:
31504302
4.

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.

Thomas S, Kuncheria L, Roulstone V, Kyula JN, Mansfield D, Bommareddy PK, Smith H, Kaufman HL, Harrington KJ, Coffin RS.

J Immunother Cancer. 2019 Aug 10;7(1):214. doi: 10.1186/s40425-019-0682-1.

5.

Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis.

Wong RJ, Tran T, Kaufman H, Niles J, Gish R.

PLoS One. 2019 Aug 1;14(8):e0220612. doi: 10.1371/journal.pone.0220612. eCollection 2019.

6.

Improved exercise capacity in cyclophilin-D knockout mice associated with enhanced oxygen utilization efficiency and augmented glucose uptake via AMPK-TBC1D1 signaling nexus.

Radhakrishnan J, Baetiong A, Kaufman H, Huynh M, Leschinsky A, Fresquez A, White C, DiMario JX, Gazmuri RJ.

FASEB J. 2019 Oct;33(10):11443-11457. doi: 10.1096/fj.201802238R. Epub 2019 Jul 25.

PMID:
31339770
7.

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 Jul 4;7(1):167. doi: 10.1186/s40425-019-0640-y.

8.

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.

Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, Ӧhrling K, Kaufman HL.

J Immunother Cancer. 2019 Jun 6;7(1):145. doi: 10.1186/s40425-019-0623-z.

9.

Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.

Kagan RM, Dunn KJ, Snell GP, Nettles RE, Kaufman HW.

AIDS Res Hum Retroviruses. 2019 Aug;35(8):698-709. doi: 10.1089/AID.2019.0063. Epub 2019 Jul 10.

PMID:
31169022
10.

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma.

Bommareddy PK, Zloza A, Rabkin SD, Kaufman HL.

Oncoimmunology. 2019 Apr 7;8(7):1591875. doi: 10.1080/2162402X.2019.1591875. eCollection 2019.

11.
12.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. Review. Erratum in: J Immunother Cancer. 2019 Jul 4;7(1):167.

13.

The promise of Immuno-oncology: implications for defining the value of cancer treatment.

Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, Joseph Mattingly T 2nd, Campbell JD, Allen J, Ferris AE, Schilsky RL, Danielson D, Lichtenfeld JL, House L, Selig WKD.

J Immunother Cancer. 2019 May 17;7(1):129. doi: 10.1186/s40425-019-0594-0.

14.

Oncolytic Immunotherapy.

Hennessy ML, Bommareddy PK, Boland G, Kaufman HL.

Surg Oncol Clin N Am. 2019 Jul;28(3):419-430. doi: 10.1016/j.soc.2019.02.007. Epub 2019 Apr 5. Review.

PMID:
31079797
15.

Remote Care of Lower Extremities Ulcers: An Observational Pilot Study.

Gamus A, Kaufman H, Chodick G.

Isr Med Assoc J. 2019 Apr;21(4):265-268.

16.

Laboratory Blood-Based Testing for Lyme Disease at a National Reference Laboratory.

Lee-Lewandrowski E, Chen Z, Branda J, Baron J, Kaufman HW.

Am J Clin Pathol. 2019 Jun 5;152(1):91-96. doi: 10.1093/ajcp/aqz030.

PMID:
30985892
17.

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry.

Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF.

J Immunother Cancer. 2019 Mar 27;7(1):84. doi: 10.1186/s40425-019-0567-3.

18.

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade.

Bommareddy PK, Rabkin SD, Kaufman HL.

Oncoimmunology. 2019 Feb 3;8(4):e1571390. doi: 10.1080/2162402X.2019.1571390. eCollection 2019.

19.

A Novel Recombinant Human Collagen-based Flowable Matrix for Chronic Lower Limb Wound Management: First Results of a Clinical Trial.

Wiser I, Tamir E, Kaufman H, Keren E, Avshalom S, Klein D, Heller L, Shapira E.

Wounds. 2019 Apr;31(4):103-107. Epub 2019 Feb 14.

20.

Synchronous video telemedicine in lower extremities ulcers treatment: A real-world data study.

Gamus A, Keren E, Kaufman H, Chodick G.

Int J Med Inform. 2019 Apr;124:31-36. doi: 10.1016/j.ijmedinf.2019.01.009. Epub 2019 Jan 14.

PMID:
30784424
21.

Two roads for oncolytic immunotherapy development.

Kaufman HL, Bommareddy PK.

J Immunother Cancer. 2019 Feb 1;7(1):26. doi: 10.1186/s40425-019-0515-2.

22.

Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma.

Ugolini H, Bryan J, Hennessy M, Kaufman HL, D'Angelo S.

Clin J Oncol Nurs. 2019 Feb 1;23(1):E1-E9. doi: 10.1188/19.CJON.E1-E9.

PMID:
30682006
23.

MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.

Bommareddy PK, Aspromonte S, Zloza A, Rabkin SD, Kaufman HL.

Sci Transl Med. 2018 Dec 12;10(471). pii: eaau0417. doi: 10.1126/scitranslmed.aau0417.

PMID:
30541787
24.

Hepatitis C Virus in Women of Childbearing Age, Pregnant Women, and Children.

Schillie SF, Canary L, Koneru A, Nelson NP, Tanico W, Kaufman HW, Hariri S, Vellozzi CJ.

Am J Prev Med. 2018 Nov;55(5):633-641. doi: 10.1016/j.amepre.2018.05.029.

PMID:
30342628
25.

Drug Misuse and Hepatitis C Virus Infection Profiles for Three Generations of Patients Being Monitored for Prescription Drug Adherence.

McClure FL, Niles JK, Kaufman HW, Gudin J.

J Addict Med. 2019 Mar/Apr;13(2):123-130. doi: 10.1097/ADM.0000000000000460.

26.

Quality Improvement to Demonstrate the Lack of Reliability of the Human Papillomavirus mRNA Assay to Identify Women With Latent Human Papillomavirus Infections.

Kaufman HW, Hilborne LH, Alagia DP.

Obstet Gynecol. 2018 Sep;132(3):778. doi: 10.1097/AOG.0000000000002827. No abstract available.

PMID:
30134394
27.

Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.

Kaufman HL, Schwartz LH, William WN Jr, Sznol M, Fahrbach K, Xu Y, Masson E, Vergara-Silva A.

J Cancer Res Clin Oncol. 2018 Nov;144(11):2245-2261. doi: 10.1007/s00432-018-2738-x. Epub 2018 Aug 21. Review.

PMID:
30132118
28.

Topical oxygen therapy stimulates healing in difficult, chronic wounds: a tertiary centre experience.

Kaufman H, Gurevich M, Tamir E, Keren E, Alexander L, Hayes P.

J Wound Care. 2018 Jul 2;27(7):426-433. doi: 10.12968/jowc.2018.27.7.426.

PMID:
30016136
29.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.

J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review.

30.

Q fever: an under-reported reportable communicable disease.

Kaufman HW, Chen Z, Radcliff J, Batterman HJ, Leake J.

Epidemiol Infect. 2018 Jul;146(10):1240-1244. doi: 10.1017/S0950268818001395. Epub 2018 Jun 26.

PMID:
29941056
31.

Avelumab: is it time to get excited?

Marciscano AE, Gulley JL, Kaufman HL.

Expert Rev Anticancer Ther. 2018 Sep;18(9):815-821. doi: 10.1080/14737140.2018.1493380. Epub 2018 Jul 2. No abstract available.

PMID:
29939083
32.

Author Correction: Integrating oncolytic viruses in combination cancer immunotherapy.

Bommareddy PK, Shettigar M, Kaufman HL.

Nat Rev Immunol. 2018 Aug;18(8):536. doi: 10.1038/s41577-018-0031-5.

PMID:
29930315
33.

Immune oncology, immune responsiveness and the theory of everything.

Turan T, Kannan D, Patel M, Matthew Barnes J, Tanlimco SG, Lu R, Halliwill K, Kongpachith S, Kline DE, Hendrickx W, Cesano A, Butterfield LH, Kaufman HL, Hudson TJ, Bedognetti D, Marincola F, Samayoa J.

J Immunother Cancer. 2018 Jun 5;6(1):50. doi: 10.1186/s40425-018-0355-5.

34.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL.

J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6.

35.

Validation of "Wound QoL" Hebrew version disease-specific questionnaire for patients with lower extremity ulcerations.

Gamus A, Kaufman H, Keren E, Brandin G, Peles D, Chodick G.

Int Wound J. 2018 Aug;15(4):600-604. doi: 10.1111/iwj.12903. Epub 2018 May 24.

PMID:
29797545
36.

Integrating oncolytic viruses in combination cancer immunotherapy.

Bommareddy PK, Shettigar M, Kaufman HL.

Nat Rev Immunol. 2018 Aug;18(8):498-513. doi: 10.1038/s41577-018-0014-6. Review. Erratum in: Nat Rev Immunol. 2018 Jun 21;:.

PMID:
29743717
37.

Management of Metastatic Melanoma in 2018.

Kaufman HL, Margolin K, Sullivan R.

JAMA Oncol. 2018 Jun 1;4(6):857-858. doi: 10.1001/jamaoncol.2018.0170. Review. No abstract available.

PMID:
29621376
38.

Juvenile probation officers' evaluation of traumatic event exposures and traumatic stress symptoms as responsivity factors in risk assessment and case planning.

Holloway ED, Cruise KR, Morin SL, Kaufman H, Steele RD.

Law Hum Behav. 2018 Aug;42(4):369-384. doi: 10.1037/lhb0000283. Epub 2018 Apr 5.

PMID:
29620395
39.

Immunotherapy for Merkel cell carcinoma: a turning point in patient care.

Chan IS, Bhatia S, Kaufman HL, Lipson EJ.

J Immunother Cancer. 2018 Mar 23;6(1):23. doi: 10.1186/s40425-018-0335-9. Review.

40.

Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.

D'Angelo SP, Russell J, Lebbé C, Chmielowski B, Gambichler T, Grob JJ, Kiecker F, Rabinowits G, Terheyden P, Zwiener I, Bajars M, Hennessy M, Kaufman HL.

JAMA Oncol. 2018 Sep 1;4(9):e180077. doi: 10.1001/jamaoncol.2018.0077. Epub 2018 Sep 13.

41.

AzBio Speech Understanding Performance in Quiet and Noise in High Performing Cochlear Implant Users.

Brant JA, Eliades SJ, Kaufman H, Chen J, Ruckenstein MJ.

Otol Neurotol. 2018 Jun;39(5):571-575. doi: 10.1097/MAO.0000000000001765.

PMID:
29557842
42.

Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.

Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino J, Stein M, El-Deiry WS.

J Clin Invest. 2018 Jun 1;128(6):2325-2338. doi: 10.1172/JCI96711. Epub 2018 Apr 30.

43.

Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences.

Kaufman HL, Dias Barbosa C, Guillemin I, Lambert J, Mahnke L, Bharmal M.

Patient. 2018 Aug;11(4):439-449. doi: 10.1007/s40271-018-0301-0.

44.

Unleashing the therapeutic potential of oncolytic viruses.

Bommareddy PK, Kaufman HL.

J Clin Invest. 2018 Apr 2;128(4):1258-1260. doi: 10.1172/JCI120303. Epub 2018 Mar 5.

45.

Quantitative Analysis of Immune Infiltrates in Primary Melanoma.

Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, Blake Z, Lu Y, Askin KN, Monod A, Esancy CL, Stack EC, Jia DT, Armenta PM, Fu Y, Izaki D, Taback B, Rabadan R, Kaufman HL, Drake CG, Horst BA, Saenger YM.

Cancer Immunol Res. 2018 Apr;6(4):481-493. doi: 10.1158/2326-6066.CIR-17-0360. Epub 2018 Feb 21.

46.

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.

Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Milella M, Brownell I, Lewis KD, Lorch JH, von Heydebreck A, Hennessy M, Nghiem P.

J Immunother Cancer. 2018 Jan 19;6(1):7. doi: 10.1186/s40425-017-0310-x.

47.

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.

Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, Singh J, Kaur M, Luna TL, Gregory N, Morse MA, Wong MKK, Dutcher JP.

J Immunother Cancer. 2017 Dec 19;5(1):102. doi: 10.1186/s40425-017-0307-5.

48.

Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma.

Kaufman HL, Hunger M, Hennessy M, Schlichting M, Bharmal M.

Future Oncol. 2018 Feb;14(3):255-266. doi: 10.2217/fon-2017-0470. Epub 2017 Dec 8.

49.

Metastasectomy following incomplete response to high-dose interleukin-2.

Hughes T, Broucek J, Iodice G, Bommareddy PK, Basu S, Kaufman HL.

J Surg Oncol. 2018 Mar;117(4):572-578. doi: 10.1002/jso.24916. Epub 2017 Nov 22.

PMID:
29165819
50.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group.

J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.

Supplemental Content

Loading ...
Support Center